Phase I/II study of chemoprevention with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (OSI-774, Tarceva) and cyclooxygenase-2 (COX-2) inhibitor (Celecoxib) in premalignant lesions of head and neck of former smokers.

Trial Profile

Phase I/II study of chemoprevention with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (OSI-774, Tarceva) and cyclooxygenase-2 (COX-2) inhibitor (Celecoxib) in premalignant lesions of head and neck of former smokers.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs Celecoxib (Primary) ; Erlotinib (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Feb 2013 Planned end date changed from 1 Oct 2015 to 1 Nov 2013 as reported by ClinicalTrials.gov.
    • 22 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 May 2011 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top